{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:28:40Z","timestamp":1776299320240,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,21]]},"DOI":"10.7759\/cureus.76130","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T13:56:32Z","timestamp":1734789392000},"source":"Crossref","is-referenced-by-count":1,"title":["The Role of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Treating Lupus Nephritis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Stephanie","family":"Nagy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Systemic lupus erythematosus. epidemiology and pathogenesis. (2024). https:\/\/www.uptodate.com\/contents\/systemic-lupus-erythematosus-epidemiology-and-pathogenesis."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian J","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023, 82:351-6. 10.1136\/ard-2022-223035","journal-title":"Ann Rheum Dis"},{"key":"ref3","article-title":"Systemic lupus erythematosus","author":"Vaillant A","year":"2023","unstructured":"Vaillant A, Goyal A, Varacallo M. Systemic lupus erythematosus. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000696","article-title":"High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions","volume":"5","author":"Barcellos LF","year":"2009","unstructured":"Barcellos LF, May SL, Ramsay PP, et al.. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 2009, 5:e1000696. 10.1371\/journal.pgen.1000696","journal-title":"PLoS Genet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.246058","article-title":"Association of HLA-DR3 and HLA-DR15 polymorphisms with risk of systemic lupus erythematosus","volume":"131","author":"Xue K","year":"2018","unstructured":"Xue K, Niu WQ, Cui Y. Association of HLA-DR3 and HLA-DR15 polymorphisms with risk of systemic lupus erythematosus. Chin Med J (Engl). 2018, 131:2844-51. 10.4103\/0366-6999.246058","journal-title":"Chin Med J (Engl)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201827","article-title":"Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE","volume":"15","author":"Graham RR","year":"2007","unstructured":"Graham RR, Ortmann W, Rodine P, et al.. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet. 2007, 15:823-30. 10.1038\/sj.ejhg.5201827","journal-title":"Eur J Hum Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000001009","article-title":"HLA-DR genotypes in patients with systemic lupus erythematosus in Taiwan","volume":"86","author":"Yen CY","year":"2023","unstructured":"Yen CY, Wang PY, Chen KY, Tseng CC, Wu CC, Ou TT, Yen JH. HLA-DR genotypes in patients with systemic lupus erythematosus in Taiwan. J Chin Med Assoc. 2023, 86:1060-5. 10.1097\/JCMA.0000000000001009","journal-title":"J Chin Med Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial","volume":"142","author":"Buyon JP","year":"2005","unstructured":"Buyon JP, Petri MA, Kim MY, et al.. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005, 142:953-62. 10.7326\/0003-4819-142-12_part_1-200506210-00004","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri M","year":"2005","unstructured":"Petri M, Kim MY, Kalunian KC, et al.. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005, 353:2550-8. 10.1056\/NEJMoa051135","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1108\/JHR-01-2020-0025","article-title":"Influence of estrogen exposure on systemic lupus erythematosus in Bangladeshi women: a case-control study scenario","author":"Jabeen S","year":"2021","unstructured":"Jabeen S, Flora M, Rahman A. Influence of estrogen exposure on systemic lupus erythematosus in Bangladeshi women: a case-control study scenario. J Health Res. 2021, 10.1108\/JHR-01-2020-0025","journal-title":"J Health Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.673180","article-title":"Hormone-related cancer and autoimmune diseases: a complex interplay to be discovered","volume":"12","author":"Losada-Garc\u00eda A","year":"2021","unstructured":"Losada-Garc\u00eda A, Cort\u00e9s-Ram\u00edrez SA, Cruz-Burgos M, et al.. Hormone-related cancer and autoimmune diseases: a complex interplay to be discovered. Front Genet. 2021, 12:673180. 10.3389\/fgene.2021.673180","journal-title":"Front Genet"},{"key":"ref12","unstructured":"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults. (2024). https.\/\/www.uptodate.com\/contents\/clinical-manifestations-and-diagnosis-of-systemic-lupus-erythematosus-in-adults."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly JG","year":"2016","unstructured":"Hanly JG, O'Keeffe AG, Su L, et al.. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016, 55:252-62. 10.1093\/rheumatology\/kev311","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002891","article-title":"Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology registry of patients with systemic lupus erythematosus (RELESSER)","volume":"95","author":"Galindo-Izquierdo M","year":"2016","unstructured":"Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM, et al.. Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology registry of patients with systemic lupus erythematosus (RELESSER). Medicine (Baltimore). 2016, 95:e2891. 10.1097\/MD.0000000000002891","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.30293","article-title":"Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006","volume":"63","author":"Costenbader KH","year":"2011","unstructured":"Costenbader KH, Desai A, Alarc\u00f3n GS, et al.. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011, 63:1681-8. 10.1002\/art.30293","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23204","article-title":"Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus","volume":"58","author":"Brunner HI","year":"2008","unstructured":"Brunner HI, Gladman DD, Iba\u00f1ez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008, 58:556-62. 10.1002\/art.23204","journal-title":"Arthritis Rheum"},{"key":"ref17","article-title":"Lupus nephritis","author":"Musa R","year":"2023","unstructured":"Musa R, Brent L, Qurie A. Lupus nephritis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema IM","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, et al.. Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018, 93:789-96. 10.1016\/j.kint.2017.11.023","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group: KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024, 105:S1-S69. 10.1016\/j.kint.2023.09.002","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet JM","year":"2022","unstructured":"Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupus nephritis management renaissance. Kidney Int. 2022, 101:242-55. 10.1016\/j.kint.2021.09.012","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh SV","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020, 76:265-81. 10.1053\/j.ajkd.2019.10.017","journal-title":"Am J Kidney Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v4.i3.176","article-title":"Kidney transplantation in patients with systemic lupus erythematosus","volume":"4","author":"Lionaki S","year":"2014","unstructured":"Lionaki S, Skalioti C, Boletis JN. Kidney transplantation in patients with systemic lupus erythematosus. World J Transplant. 2014, 4:176-82. 10.5500\/wjt.v4.i3.176","journal-title":"World J Transplant"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao EC","year":"2014","unstructured":"Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014, 32:4-11. 10.2337\/diaclin.32.1.4","journal-title":"Clin Diabetes"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey CJ","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022, 22:39-52. 10.1007\/s11892-021-01442-z","journal-title":"Curr Diab Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris E","year":"2015","unstructured":"Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015, 13:132-40. 10.1097\/XEB.0000000000000055","journal-title":"Int J Evid Based Healthc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578","article-title":"Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus","volume":"7","author":"Yen FS","year":"2024","unstructured":"Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024, 7:e2416578. 10.1001\/jamanetworkopen.2024.16578","journal-title":"JAMA Netw Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang H","year":"2022","unstructured":"Wang H, Li T, Sun F, et al.. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial. RMD Open. 2022, 8:10.1136\/rmdopen-2022-002686","journal-title":"RMD Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao XY","year":"2023","unstructured":"Zhao XY, Li SS, He YX, et al.. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023, 82:1328-40. 10.1136\/ard-2023-224242","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20233411S1268c","article-title":"Interim analysis of dapagliflozin in inactive lupus nephritis cross-over randomized trial","volume":"34","author":"Vajgel G","year":"2023","unstructured":"Vajgel G, Filho C, Miranda S, et al.. Interim analysis of dapagliflozin in inactive lupus nephritis cross-over randomized trial. JASN. 2023, 34:268-9. 10.1681\/ASN.20233411S1268c","journal-title":"JASN"},{"key":"ref31","article-title":"Il-1b and NLRP33 gene expression profile with dapagliflozin in inactive lupus nephritis","author":"Vajgel G","year":"2023","unstructured":"Vajgel G, Braziliano J, Oliveira C, et al.. Il-1b and NLRP33 gene expression profile with dapagliflozin in inactive lupus nephritis. Universidade Federal de Pernambuco, 2023."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03508-1","article-title":"Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies","volume":"79","author":"Elkeraie A","year":"2023","unstructured":"Elkeraie A, Zyada R, Elrggal ME, Elrggal M. Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies. Eur J Clin Pharmacol. 2023, 79:961-6. 10.1007\/s00228-023-03508-1","journal-title":"Eur J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.01.016","article-title":"Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis","volume":"9","author":"Gatto M","year":"2024","unstructured":"Gatto M, Frontini G, Calatroni M, et al.. Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis. Kidney Int Rep. 2024, 9:1047-56. 10.1016\/j.ekir.2024.01.016","journal-title":"Kidney Int Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen YE","year":"2008","unstructured":"Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008, 3:46-53. 10.2215\/CJN.03280807","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000533","article-title":"Absence of renal remission portends poor long-term kidney outcome in lupus nephritis","volume":"8","author":"Pirson V","year":"2021","unstructured":"Pirson V, Enfrein A, Houssiau FA, Tamirou F. Absence of renal remission portends poor long-term kidney outcome in lupus nephritis. Lupus Sci Med. 2021, 8:10.1136\/lupus-2021-000533","journal-title":"Lupus Sci Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson A","year":"2016","unstructured":"Davidson A. What is damaging the kidney in lupus nephritis?. Nat Rev Rheumatol. 2016, 12:143-53. 10.1038\/nrrheum.2015.159","journal-title":"Nat Rev Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000230","article-title":"Management of lupus nephritis: new treatments and updated guidelines","volume":"4","author":"Avasare R","year":"2023","unstructured":"Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of lupus nephritis: new treatments and updated guidelines. Kidney360. 2023, 4:1503-11. 10.34067\/KID.0000000000000230","journal-title":"Kidney360"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin BH","year":"2019","unstructured":"Rovin BH, Solomons N, Pendergraft WF 3rd, et al.. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019, 95:219-31. 10.1016\/j.kint.2018.08.025","journal-title":"Kidney Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin B","year":"2021","unstructured":"Rovin B, Teng K, Ginzler E, et al.. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021, 397:2070-80. 10.1016\/S0140-6736(21)00578-X","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie R","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020, 383:1117-28. 10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103377","article-title":"Nephroprotective properties of antidiabetic drugs","volume":"12","author":"Gerdes C","year":"2023","unstructured":"Gerdes C, M\u00fcller N, Wolf G, Busch M. Nephroprotective properties of antidiabetic drugs. J Clin Med. 2023, 12:10.3390\/jcm12103377","journal-title":"J Clin Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019, 139:2022-31. 10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02317.x","article-title":"Advanced glycation end-products and the kidney","volume":"40","author":"Busch M","year":"2010","unstructured":"Busch M, Franke S, R\u00fcster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest. 2010, 40:742-55. 10.1111\/j.1365-2362.2010.02317.x","journal-title":"Eur J Clin Invest"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle KR","year":"2022","unstructured":"Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022, 102:248-60. 10.1016\/j.kint.2022.05.012","journal-title":"Kidney Int"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.391894","article-title":"Levels of proteinuria and renal pathology in systemic lupus erythematosus patients","volume":"34","author":"Al Arfaj AS","year":"2023","unstructured":"Al Arfaj AS, Khalil N. Levels of proteinuria and renal pathology in systemic lupus erythematosus patients. Saudi J Kidney Dis Transpl. 2023, 34:154-60. 10.4103\/1319-2442.391894","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.12659\/msm.899973","article-title":"Urinary albumin levels are independently associated with renal lesion severity in patients with lupus nephritis and little or no proteinuria","volume":"23","author":"Ding J","year":"2017","unstructured":"Ding J, Zheng Z, Li X, Feng Y, Leng N, Wu Z, Zhu P. Urinary albumin levels are independently associated with renal lesion severity in patients with lupus nephritis and little or no proteinuria. Med Sci Monit. 2017, 23:631-9. 10.12659\/msm.899973","journal-title":"Med Sci Monit"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000684","article-title":"One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria","volume":"9","author":"Weeding E","year":"2022","unstructured":"Weeding E, Fava A, Magder L, Goldman D, Petri M. One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria. Lupus Sci Med. 2022, 9:10.1136\/lupus-2022-000684","journal-title":"Lupus Sci Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320966393","article-title":"Predictors of the start of declining eGFR in patients with systemic lupus erythematosus","volume":"30","author":"Yip TC","year":"2021","unstructured":"Yip TC, Saria S, Petri M, Magder LS. Predictors of the start of declining eGFR in patients with systemic lupus erythematosus. Lupus. 2021, 30:15-24. 10.1177\/0961203320966393","journal-title":"Lupus"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091340","article-title":"Podocyte injury in lupus nephritis","volume":"8","author":"Sakhi H","year":"2019","unstructured":"Sakhi H, Moktefi A, Bouachi K, et al.. Podocyte injury in lupus nephritis. J Clin Med. 2019, 8:10.3390\/jcm8091340","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/art.40155","article-title":"Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis","volume":"69","author":"Fu R","year":"2017","unstructured":"Fu R, Guo C, Wang S, et al.. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 2017, 69:1636-46. 10.1002\/art.40155","journal-title":"Arthritis Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320443-the-role-of-sodium-glucose-co-transporter-2-sglt-2-inhibitors-in-treating-lupus-nephritis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T13:56:35Z","timestamp":1734789395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320443-the-role-of-sodium-glucose-co-transporter-2-sglt-2-inhibitors-in-treating-lupus-nephritis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.76130","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,21]]}}}